ECSP14018630A - Formulaciones farmacéuticas novedosas - Google Patents

Formulaciones farmacéuticas novedosas

Info

Publication number
ECSP14018630A
ECSP14018630A ECIEPI201418630A ECPI201418630A ECSP14018630A EC SP14018630 A ECSP14018630 A EC SP14018630A EC IEPI201418630 A ECIEPI201418630 A EC IEPI201418630A EC PI201418630 A ECPI201418630 A EC PI201418630A EC SP14018630 A ECSP14018630 A EC SP14018630A
Authority
EC
Ecuador
Prior art keywords
particulate
metal salts
pharmaceutical formulations
novel pharmaceutical
inamide
Prior art date
Application number
ECIEPI201418630A
Other languages
English (en)
Inventor
Filip Marcel C Vanhoutte
Walter Ferdinand Maria Filliers
Carina Leys
Patrick Hubert J Nieste
Alex Herman Copmans
Rudy Laurent Maria Broeckx
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14018630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of ECSP14018630A publication Critical patent/ECSP14018630A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona inter alia una formulación farmacéutica en polvo seco para inhalación que comprende: (i) 6-(2-((4-amino-3-(3-hidroxifenil)-1 H-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-clorobencil)-4-oxo-3,4-dihidroquinazolin-5-il)-N,N-bis(2-metoxietil)hex-5-inamida o una sal farmacéuticamente aceptable del mismo, incluyendo todos los estereoisómeros, tautómeros y derivados isotópicos del mismo y solvatos del mismo en forma particulada como ingrediente activo; (ii) lactosa particulada como portador; y (iii) un agente estabilizador particulado seleccionado de sales metálicas de ácido esteárico como estearato de magnesio y sales metálicas de estearil fumarato.
ECIEPI201418630A 2012-03-13 2014-09-12 Formulaciones farmacéuticas novedosas ECSP14018630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13

Publications (1)

Publication Number Publication Date
ECSP14018630A true ECSP14018630A (es) 2015-09-30

Family

ID=49160309

Family Applications (2)

Application Number Title Priority Date Filing Date
ECIEPI201418142A ECSP14018142A (es) 2012-03-13 2014-09-10 Inhibidores de cinasa de fosfoinositida 3 cristalina
ECIEPI201418630A ECSP14018630A (es) 2012-03-13 2014-09-12 Formulaciones farmacéuticas novedosas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECIEPI201418142A ECSP14018142A (es) 2012-03-13 2014-09-10 Inhibidores de cinasa de fosfoinositida 3 cristalina

Country Status (36)

Country Link
US (3) US9642799B2 (es)
EP (2) EP2834244B1 (es)
JP (3) JP6189874B2 (es)
KR (2) KR20140141596A (es)
CN (2) CN104284679B (es)
AU (2) AU2013234080B2 (es)
CA (2) CA2864652A1 (es)
CL (2) CL2014002386A1 (es)
CO (2) CO7051030A2 (es)
CR (2) CR20140417A (es)
CY (1) CY1118565T1 (es)
DK (1) DK2834244T3 (es)
EA (2) EA023715B1 (es)
EC (2) ECSP14018142A (es)
ES (2) ES2600705T3 (es)
GT (2) GT201400182A (es)
HK (2) HK1203487A1 (es)
HR (1) HRP20161383T1 (es)
HU (1) HUE029420T2 (es)
IL (2) IL233886A (es)
IN (2) IN2014MN01998A (es)
LT (1) LT2834244T (es)
MX (2) MX357170B (es)
MY (1) MY171125A (es)
NI (2) NI201400100A (es)
NZ (2) NZ628072A (es)
PE (2) PE20142342A1 (es)
PH (2) PH12014501713A1 (es)
PL (1) PL2834244T3 (es)
PT (1) PT2834244T (es)
SG (2) SG11201404522VA (es)
SI (1) SI2834244T1 (es)
TW (2) TWI617561B (es)
UA (1) UA115544C2 (es)
WO (2) WO2013136075A1 (es)
ZA (2) ZA201407373B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
SI2834244T1 (sl) 2012-03-13 2016-12-30 Respivert Limited Inhibitorji kristalinične PI3 kinaze
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2916868B1 (en) 2012-11-08 2022-05-11 Rhizen Pharmaceuticals S.A. Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
JP6291601B2 (ja) 2014-07-04 2018-03-14 ルピン・リミテッド Pi3k阻害剤としてのキノリジノン誘導体
EP3166641B1 (en) 2014-07-09 2018-09-12 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20180058741A (ko) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP7166929B2 (ja) 2016-04-15 2022-11-08 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
CA2347856C (en) 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
HUP0200185A3 (en) 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Nadシンテターゼ阻害剤およびその使用
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
JP2007524605A (ja) 2003-04-03 2007-08-30 ピーディーエル バイオファーマ,インコーポレイティド インテグリンα5β1のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
US20100267778A1 (en) 2003-08-04 2010-10-21 Shinya Kusuda Diphenyl ether compound, process for producing the same, and use
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
RS55551B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
CA2730540A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
MX2007002886A (es) 2004-09-13 2007-05-16 Ono Pharmaceutical Co Derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo.
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006089106A2 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
PT2004654E (pt) 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
CN101448505A (zh) * 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
BRPI0711796A2 (pt) 2006-05-24 2011-12-06 Bayer Schering Pharma Aktiendesellschaft anticorpos de bloqueio de função de integrinas anti-alfa5beta1 humanos e humanizados com imunogenicidade reduzida
AR061664A1 (es) 2006-06-29 2008-09-10 Schering Corp Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US8362066B2 (en) 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
MX2009012066A (es) * 2007-05-09 2009-11-19 Novartis Ag Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
WO2010065923A2 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
IN2012DN01254A (es) 2009-08-05 2015-05-15 Versitech Ltd
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) * 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) * 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
AU2011298315B2 (en) * 2010-08-31 2014-08-28 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2621494B1 (en) 2010-09-30 2018-11-07 Chiesi Farmaceutici S.p.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) * 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
SI2834244T1 (sl) 2012-03-13 2016-12-30 Respivert Limited Inhibitorji kristalinične PI3 kinaze

Also Published As

Publication number Publication date
DK2834244T3 (en) 2016-11-28
EA025465B1 (ru) 2016-12-30
PE20141964A1 (es) 2014-12-01
NZ627963A (en) 2015-08-28
CL2014002386A1 (es) 2015-02-27
HRP20161383T1 (hr) 2016-12-02
SI2834244T1 (sl) 2016-12-30
CR20140416A (es) 2014-10-31
CN104284679A (zh) 2015-01-14
CO7051030A2 (es) 2014-09-10
AU2013234081B2 (en) 2017-02-02
SG11201404519UA (en) 2014-10-30
JP2018008992A (ja) 2018-01-18
HK1203487A1 (zh) 2015-10-30
AU2013234080A1 (en) 2014-08-21
LT2834244T (lt) 2016-11-10
AU2013234080B2 (en) 2016-12-22
UA115544C2 (uk) 2017-11-27
IL233886A (en) 2017-12-31
JP6189874B2 (ja) 2017-08-30
PH12014501713A1 (en) 2014-10-13
WO2013136076A1 (en) 2013-09-19
PL2834244T3 (pl) 2017-01-31
CA2864652A1 (en) 2013-09-19
CN104284679B (zh) 2017-08-04
EP2834244B1 (en) 2016-08-10
CR20140417A (es) 2014-10-31
KR20140131971A (ko) 2014-11-14
WO2013136075A1 (en) 2013-09-19
MX2014010990A (es) 2014-10-13
NZ628072A (en) 2015-08-28
MX355299B (es) 2018-04-11
NI201400100A (es) 2015-01-12
IN2014MN02000A (es) 2015-08-14
GT201400183A (es) 2015-07-08
EP2825202B1 (en) 2017-09-06
SG11201404522VA (en) 2014-10-30
TWI617561B (zh) 2018-03-11
PE20142342A1 (es) 2015-01-16
KR20140141596A (ko) 2014-12-10
TW201350139A (zh) 2013-12-16
GT201400182A (es) 2015-09-17
US20150105408A1 (en) 2015-04-16
TW201400484A (zh) 2014-01-01
US9642799B2 (en) 2017-05-09
IN2014MN01998A (es) 2015-08-14
NI201400101A (es) 2016-11-30
HK1203812A1 (en) 2015-11-06
HUE029420T2 (en) 2017-02-28
EA201491675A1 (ru) 2014-12-30
US20170239256A1 (en) 2017-08-24
TWI586378B (zh) 2017-06-11
CY1118565T1 (el) 2017-07-12
EP2825202A1 (en) 2015-01-21
ES2600705T3 (es) 2017-02-10
AU2013234081A1 (en) 2014-08-21
EA023715B1 (ru) 2016-07-29
CL2014002385A1 (es) 2015-01-09
CN104302650A (zh) 2015-01-21
JP2015509973A (ja) 2015-04-02
CA2864643A1 (en) 2013-09-19
PH12014501922A1 (en) 2014-11-24
EP2834244A1 (en) 2015-02-11
MY171125A (en) 2019-09-26
ECSP14018142A (es) 2015-06-30
CO7061079A2 (es) 2014-09-19
EA201491674A1 (ru) 2014-12-30
ZA201407373B (en) 2016-10-26
MX2014010991A (es) 2014-10-13
ES2650791T3 (es) 2018-01-22
IL233883A0 (en) 2014-09-30
MX357170B (es) 2018-06-27
US20150099768A1 (en) 2015-04-09
CN104302650B (zh) 2017-07-18
ZA201407374B (en) 2016-10-26
JP2015509972A (ja) 2015-04-02
PT2834244T (pt) 2016-11-03

Similar Documents

Publication Publication Date Title
ECSP14018630A (es) Formulaciones farmacéuticas novedosas
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
AU2017245301A1 (en) Pharmaceutical combinations
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PE20150998A1 (es) Inhibidores de histona demetilasas
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
JP2014505735A5 (es)
AR083422A1 (es) Composiciones y metodos para tratar la hipertension pulmonar
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
BR112017012566A2 (pt) formulações farmacêuticas de inibidores de cinases relacionadas à tropomiosina (trk)
AR107935A1 (es) Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto
HRP20210691T1 (hr) Farmaceutski oblici doziranja koji sadrže natrij 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olat
MY166556A (en) Pharmaceutical formulation for topical administration comprising b220
TH156275A (th) สูตรผสมทางเภสัชกรรมชนิดใหม่
TH156276A (th) ตัวยับยั้ง pi3 ไคเนสที่เป็นผลึก
TH164080B (th) รูปเเบบยาของเเข็ง
CU20060219A7 (es) Formulaciones con liberación controlada de principio activo que contiene vardenafilo
CO6280050A1 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa